| ICIs | Immune checkpoint inhibitors |
| SGLT-2 | Sodium-glucose cotransporter type-2 |
| NLRP3 | NOD-like receptor family pyrin domain, containing 3 |
| MyD88 | Myddosome type 88 |
| PD1 | Programmed cell death protein 1 |
| PDL1 | Programmed Death-Ligand 1 |
| CTLA4 | Cytotoxic T-Lymphocyte Antigen 4 |
| AMPK | 5’ AMP-activated protein kinase |
| hs-CRP | High sensitivity C-reactive protein |
| ROS | Reactive oxygen species |
| MDA | Malondialdeyde |
| p65-NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| ILs | Interleukins |
| PDGF | Platelet-Derived Growth Factor |
| VEGF | Vascular endothelia growth factor |
| TGF-β | Transforming growth factor beta |
| AGEs | Advanced glycation end products |
| CVOTs | Cardiovascular outcome trials |
| VEGF | Vascular endothelia growth factor |
| TGF-β | Transforming growth factor beta |
| AGEs | Advanced glycation end products |